Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 9/20 | 0.74 |
| ▸ | TYR | P14679 | 1/20 | 0.60 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.46 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16218784 | 0.86 | TYR (0.60) | CYP19A1TYRHSP90AB1NOTUMJAK2 | |
| SCHEMBL16219151 | 0.86 | TYR (0.60) | CYP19A1TYRHSP90AB1NOTUMJAK2 | |
| SCHEMBL2641384 | 0.85 | CYP19A1 (1.00) | CYP19A1HSP90AB1MAOAMAOB | |
| SCHEMBL21557005 | 0.84 | TYR (0.58) | CYP19A1TYRHSP90AB1NOTUM | |
| SCHEMBL16401421 | 0.80 | TYR (0.59) | CYP19A1TYRNOTUMJAK2ROCK2 | |
| Acetic Acid SCHEMBL28328685 | 0.79 | CYP19A1 (0.86) | CYP19A1HSP90AB1MAOAMAOB | |
| SCHEMBL28533317 | 0.75 | CYP19A1 (0.97) | CYP19A1HSP90AB1MAOAMAOB | |
| SCHEMBL10044916 | 0.74 | CYP19A1 (1.00) | CYP19A1HSP90AB1MAOAMAOB | |
| SCHEMBL2193998 | 0.74 | CYP19A1 (1.00) | CYP19A1HSP90AB1MAOAMAOB | |
| SCHEMBL16219152 | 0.73 | TYR (0.52) | CYP19A1TYRNOTUMJAK2ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170266326-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-9550000-B2 | Compositions, methods, and systems for the synthesis and use of imaging agents | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20140328756-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2014-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266326-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | CYP19A1 2566/4885TYR 1231/4885HSP90AB1 1763/4885 |
| US-20140328756-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | CYP19A1 2566/4885TYR 1231/4885HSP90AB1 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.